default author photo

Tilmann Bochtler

German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology

Heidelberg, 69120

Germany

Thoraxklinik Heidelberg - Department of Thoracic Oncology

Heidelberg

Germany

  • German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology

  • Thoraxklinik Heidelberg - Department of Thoracic Oncology

SCHOLARLY PAPERS

1

DOWNLOADS

57

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary

Number of pages: 51 Posted: 28 Sep 2019
Tilmann Bochtler, Anna Reiling, Volker Endris, Thomas Hielscher, Anna-Lena Volckmar, Olaf Neumann, Martina Kirchner, Jan Budczies, Lukas C. Heukamp, Jonas Leichsenring, Michael Allgäuer, Daniel Kazdal, Harald Löffler, Wilko Weichert, Peter Schirmacher, Albrecht Stenzinger and Alwin Krämer
German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg University - Institute of Pathology, German Cancer Research Center (DKFZ) - Division of Biostatistics, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Institute for Haematopathology Hamburg, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology, Heidelberg University - Institute of Pathology and German Cancer Research Center (DKFZ) - Clinical Cooperation Unit Molecular Hematology/Oncology
Downloads 57 (1,000,027)

Abstract:

Loading...

Cancer of unknown primary (CUP), mutational profiling, KRAS, CDKN2A, prognosis, targeted therapy